

ALL WALES PRESCRIBING ADVISORY GROUP

**DRAFT Minutes of meeting held on
Wednesday 19 September 2018 commencing 9.30 am
At the Angel Hotel, Cardiff**

Voting members

| | |
|---------------------------------|---|
| Dr Lisa Adams | General Practitioner, Abertawe Bro Morgannwg |
| Mrs Jane Barnard | Lay member |
| Dr Rob Bracchi | AWTTC |
| Mr Alan Clatworthy | Pharmacist, Abertawe Bro Morgannwg |
| Mr Mike Curson | Pharmacist, Aneurin Bevan |
| Miss Sian Evans | Consultant in Pharmaceutical Public Health, PHW |
| Dr Laurence Gray | Consultant, Cardiff and Vale |
| Mrs Louise Howard-Baker (Chair) | Pharmacist, Betsi Cadwaladr |
| Dr Sue Jeffs | Consultant, Aneurin Bevan |
| Mr Dylan Jones | Community Pharmacist, Powys |
| Dr Becky McGee | General Practitioner, Aneurin Bevan |
| Mrs Robyn Miles | ABPI Wales Industry Group |
| Mrs Bethan Tranter | Chief Pharmacist, Velindre |
| Ms Fiona Walker | Pharmacist, Cardiff and Vale |
| Mrs Bev Woods | Pharmacist, Cwm Taf |
| Ms Cathy Wynne | Physiotherapy Lead, Betsi Cadwaladr |

In attendance (non-voting)

| | |
|------------------------|--|
| Mr Richard Boldero | AWTTC |
| Miss Christine Collier | AWTTC |
| Mr Thomas Curran | AWTTC |
| Mr Paul Deslandes | AWTTC |
| Ms Kath Haines | AWTTC |
| Mr David Lewis | AWTTC |
| Miss Laura Phillips | AWTTC |
| Mrs Claire Thomas | AWTTC |
| Prof Susan Jordan | Swansea University |
| Dr Nicholas Reid | Consultant Antimicrobial Pharmacist, PHW |
| Dr Alan Willson | Swansea University |

Key of abbreviations

| | |
|-------|--|
| ABPI | Association of the British Pharmaceutical Industry |
| AWMSG | All Wales Medicines Strategy Group |
| AWTTC | All Wales Therapeutics and Toxicology Centre |
| CEPP | Clinical Effectiveness Prescribing Programme |
| NICE | National Institute for Health and Care Excellence |
| NPIs | National Prescribing Indicators |
| NWIS | NHS Wales Informatics Service |
| OTC | Over the counter |
| PHW | Public Health Wales |

DRAFT

1.0 Welcome & introduction

The Chair welcomed members and covered general housekeeping. The Chair welcomed Cathy Wynne to the group as a new deputy member and asked individuals to introduce themselves.

2.0 Apologies

| | |
|--------------------|---|
| Ms Sue Beach | Pharmacist, Hywel Dda |
| Dr Richard Brown | General Practitioner, Hywel Dda |
| Mrs Clare Clement | Prescribing Advisor, Cardiff and Vale |
| Mr Aled Falvey | Clinical Specialist Physiotherapist, Powys |
| Mr Paul Fleming | British Generics Manufacturers |
| Dr Rick Greville | ABPI |
| Mr Jamie Hayes | AWTTC |
| Mrs Sarah Isaac | Pharmacist, Hywel Dda |
| Ms Lynette James | Pharmacist, Cardiff and Vale |
| Dr Sally Lewis | Assistant Medical Director/Primary Care Clinical Director, Aneurin Bevan |
| Ms Miranda Morton | Welsh Government |
| Mrs Karen Samuels | AWTTC |
| Dr Anders Skarsten | Consultant, Powys |

3.0 Declarations of interest

The Chair asked members to declare any new interests relevant to the meeting. Robyn Miles declared an interest in the COPD pathway. As this item on the agenda was a verbal update and no discussion was intended, it was agreed that she could remain in the room for this item.

4.0 Chair's report

The Chair informed members that the AWMSG Steering Committee had approved the appointment of Dylan Jones as Community Pharmacist representative and Clare Clement as deputy Prescribing Advisor representative for Cardiff and Vale University Health Board and that Steve Simmonds has resigned as deputy community pharmacist representative. The Chair informed members that Fiona Walker, Jane Barnard and Sarah Isaac's term in office had come to an end, and today would be their last meeting. The Chair thanked them for their invaluable support of the committee over the years. The Chair informed AWPAG that replacement members and deputies have been nominated and these will be presented to the AWMSG Steering Committee on the 25 September for approval. The Chair informed members that there are currently vacancies for deputy doctors for all health boards apart from Hywel Dda and Aneurin Bevan University Health Boards, and that requests for further information regarding nominations should be directed to Anne Coles. The Chair thanked everyone for their continued commitment and valuable contribution to the work of AWPAG.

5.0 Minutes of previous meeting – June 2018

The minutes of the previous meeting were checked for accuracy. Actions of the previous meeting had been completed or were to be discussed as part of the agenda. Kath Haines gave an update on the COPD guidelines following the previous meeting, informing members that AWTTC are waiting for the final document from Dr Simon Barry. It was raised as to whether costs would be banded. Kath Haines informed members that should costs be banded this would be consulted with AWPAG members via email prior to going out for consultation. Representing the cost of the inhalers with a code or price band, rather than actual costs, was discussed; Sian Evans highlighted the importance of consistency in how information was to be presented within the tool; and Bethan Tranter said she would follow up with Mark Francis with regards to any procurement arrangements that had been discussed.

DRAFT

Alan Clatworthy raised that the Welsh Hospitals Electronic Prescribing and Pharmacy Medicines Administration (WHEPPMA), which was postponed from the last meeting, was not on the agenda. Kath Haines informed members that this session was due to come back to this meeting, but the presenter had requested to reschedule for the December meeting.

6.0 Feedback from July and September 2018 AWMSG meeting for information

These documents were discussed as part of the minutes of the previous meeting.

Dr Sue Jeffs, Bev Woods, Dylan Jones, Professor Sue Jordan, Dr Alan Willson and Dr Becky McGee joined the meeting.

7.0 Documents for discussion

Mental Health Medicines in Older Adults: the Adverse Drug Reaction (ADRe) Profile to check patients for signs and symptoms of adverse effects

Professor Sue Jordan and Dr Alan Willson from Swansea University presented the *Mental Health Medicines in Older Adults – ADRe Profile* paper. Prof Jordan informed members that they would welcome endorsement of their document. Prof Jordan gave a background to members, including information on a trial, and said they were looking to create a personal review which would go alongside the current chart review. She asked members for their feedback on the form prior to finalisation. The Chair opened the floor for questions and discussion. The group unanimously agreed that creating awareness was key for this project. Dr Alan Willson tabled additional confidential information for members to see. Dr Robert Bracchi updated members on the presentation that Prof Sue Jordan had given at the Best Practice Day 2018 for those members who were unable to attend. The group agreed that the proposal would add value, but due to the time needed to complete the forms, all allied health professions would need to be able to complete them, rather than just relying on GPs. The group discussed who would best complete the form and what training would be required, agreeing that the document would enhance professional learning. In response to a query, Prof Jordan confirmed that discussions were underway as to how impact could be monitored going forward. Prof Jordan informed members that the form was free to use but users are required to sign up to register for the form. In response to a query, Prof Jordan confirmed that the document was currently only available in paper format, however they are looking for sponsorship to be able to create an online version – ideally they would have a clinical lead who would champion the ADRe profile in an application to the Bevan Commission for funding. It was suggested that Prof Jordan also looks into seeking funding for this development through the Healthier Wales technology fund. The issues around who would own submitted information within a potential digital version was raised. The group agreed that they would support the paper with some agreed rewording. It was noted that AWPAG or AWMSG were not in a position to enable 'integration and adoption into the 1,000 Lives framework' therefore this sentence should be removed. The group raised that the wording in section 3.4 on page 3 may be a bit ambiguous and the rationale was discussed in detail. Prof Jordan thanked members for their help.

Dr Laurence Gray enquired as to whether the tool is used in teaching medical undergraduates as they are required to undertake work in the community, and the tool would be a useful aid. Dr Willson said this had not been done as yet, but he would be keen to explore the opportunity.

Action: Prof Sue Jordan and Dr Alan Willson to make agreed amendments before AWTTTC disseminate the paper for consultation.

Prof Sue Jordan, Dr Alan Willson and Paul Deslandes left the meeting

DRAFT

National Prescribing Indicators 2019–2020

Claire Thomas presented to members each indicator and clarified that the opioid patches and antimicrobial prophylaxis in colorectal surgery indicators are proposed to be retired. Members asked Claire Thomas to clarify why sodium valproate use in females would be reported as a percentage rather than total number of patients. Claire Thomas informed members that the percentage would be used to allow comparison with England, however total number of patients could also be reported

The antimicrobial stewardship indicators were discussed and it was agreed that volume of antibacterials in secondary care would be reported by health board and hospital, with data provided quarterly by PHW. The 4C antimicrobials for primary care would be retained, however this would not be monitored in secondary care. The WHO AWaRe 'Access' list would be introduced for secondary care with a baseline of 2017 calendar year, as per the UK target. Dr Nik Reid confirmed that PHW would provide data at a health board and hospital level for this indicator. Claire Thomas informed members that the proposed trimethoprim indicator for primary care was not able to go ahead for 2019–2020 within current timescales.

Richard Boldero updated members on the biosimilar NPI and informed members that adalimumab and insulin detemir have new biosimilar versions which will probably start to be included in the reports from quarter four 2018–2019 onwards. Richard Boldero informed members that filgrastim will no longer be part of the NPIs but it will still be reported via the biosimilars dashboard. Richard Boldero also informed members that the terminology within the section had been changed to “cost-efficient” following feedback on the NPI document.

Bethan Tranter queried whether trastuzumab would be included within the biosimilar monitoring basket. Richard Boldero explained that that had been the original intention, however some comments had been made around the applicability of it due to the limited number of patients eligible for biosimilar switching. It was agreed that this would be discussed further outside of the meeting with any relevant agreed action points to be brought back to members at the next meeting.

The final proposed NPI discussed was the continuation of the long-acting insulin NPI. This was supported by members. Kath Haines informed members of some work she had been made aware of in Cardiff and Vale UHB where patients who had switched from long-acting insulin analogues to suitable alternatives had seen an improved HbA1c; the work had also resulted in significant cost savings. This work had been undertaken by diabetes nurse specialists and was suggested as a potential topic for the 2019 Best Practice Day.

Action: AWTTTC to address comments and send paper for consultation in October.

Action: AWTTTC to investigate the possibility of including long acting insulin analogues as a topic for the 2019 Best Practice Day

Nik Reid left the meeting

Medicines Identified as Low Priority for Funding in NHS Wales

Kath Haines gave members a background to phase 2 of the Low Priority for Funding paper. The original paper in this phase that was sent to members had been reconsidered in light of their comments and a new set of four medicines put forward for consideration. These are:

- omega-3 fatty acid compounds
- oxycodone and naloxone combination product
- paracetamol and tramadol combination product
- perindopril arginine.

DRAFT

These were the medicines in the paper that was circulated to members prior to this meeting. Overall members were supportive of the new medicines suggested.

Kath Haines informed members that, although concerns had been noted around the inclusion of OTC medicines within the low priority work, following discussion at the All Wales Joint Pharmacy and Finance meeting held on Monday 17th September there was a consensus opinion that the whole OTC product list should be part of the low priority work. However, they agreed that AWPAG members should have the decision on the content of the list before the paper would be sent out for wider consultation. AWPAG members supported the principal of adopting the OTC document. Some concerns were raised around patient awareness and Richard Boldero informed members of a resource pack and information leaflets which have been produced by NHS England recently and could help inform patients. The group discussed the link with the community pharmacy Common Ailment Scheme and unanimously agreed that patients needed increased awareness about the scheme and where to get certain items without needing to go to their GP. The group discussed if OTCs should be included within the current phase 2 document, and decided that OTCs should be in a different document. It was agreed that members' feedback to the All Wales Pharmacy and Finance Group would be to support the current phase 2 document and for it to go out to consultation following this meeting, and that the OTC products would be considered within a different document (phase 3) which would focus on probiotics, benzydamine products, vitamins and minerals, and bath emollients.

With regards to the current phase 2 document, Richard Boldero asked for any comments from members. Some comments were raised around why cod liver oil preparations were removed from the omega-3 basket of products. It was agreed that AWTTTC would provide the amount across Wales that was spent on these products to determine whether they should be added in. Alan Clatworthy asked if the consultation could go to the Cardiac Network. Alan Clatworthy also asked if there had been any improvement in the paper 1 medicines. Richard Boldero informed members that from the dashboard information there has been an overall improvement for those medicines. Members recommended that this information is added into paper 2 to demonstrate the positive effect that the phase 1 work is having.

Action: Phase 2 paper containing 4 medicines to go out for consultation

Action: AWTTTC to ensure the Cardiac Network is on the consultation list.

Action: AWTTTC to write a separate document for OTC products in the areas of probiotics, benzydamine products, vitamins and minerals, and bath emollients

Action: KH to feedback to the All Wales Pharmacy and Finance Group.

Action: AWTTTC to add improvement noted from phase 1 to introduction of phase 2 document.

Action: AWTTTC to investigate prescribing of cod liver oil in Wales

Action: Maps for England to be removed from the PrescQIPP data

CEPP National Audit: Antipsychotics in Dementia

Claire Thomas presented the paper to members and gave a background to the project and an update on what has happened to date. Claire Thomas asked for members' comments before the paper goes out for consultation. Members fed back that the review was a good tool, however it was felt that secondary care teams have the main responsibility for reviewing patients, and reviews do not always take place in a timely manner or are undertaken but the results are not communicated to the GP. It was agreed that the audit tool would enable data to be captured to highlight this issue. It was suggested that the audit should include a question regarding who had undertaken the patient review (primary or secondary care), and whether a dose reduction or withdrawal had been attempted. Members suggested that a link to the ADRe should be included.

DRAFT

Action: AW TTC to add a column for primary/secondary care review and a column for dose reduction/withdrawal

Action: AW TTC to add link to ADRe as a resource

Therapeutic Priorities and CEPP Summary 2019–2020

Claire Thomas presented the CEPP framework and informed members that once the NPIs have been endorsed then these will be added to the document with the intention that the document is endorsed by AWMSG in early 2019. Claire Thomas asked for comments on the document. Members noted that they liked the presentation of the document and that it was user friendly. Alan Clatworthy suggested that the EMA resources on biosimilars could be included in this document and in the NPI document.

Action: AW TTC to include link to EMA biosimilar resources, (and investigate other potential biosimilar resources e.g. endorsed by Royal Colleges) for 'Therapeutic Priorities and CEPP Summary' and NPI document

Action: AW TTC to include a link to the Royal College of Anaesthetists 'Opioids Aware' resources

Action: AW TTC to present to AWMSG for endorsement in 2019

8.0 Verbal updates

All Wales COPD Management and Prescribing Guide

Kath Haines presented this at the start of the meeting (see *5.0 Minutes of previous meeting*).

Medication Review

Dr Robert Bracchi informed members of the proposal to develop a Medication Review resource, as noted in the AWMSG Strategy. It was decided that a Task and Finish Group would be created from AWPAG members to develop the resource. Dr Bracchi informed members that the objective is to produce a nationally agreed multi-professional standard for medication review. Dr Bracchi asked for members to consider if they would like to be volunteers and this would be discussed further at the December meeting. The group agreed that there should be representatives from different professional roles on the group, not just different professions, as different types of medication review are undertaken depending on the job role.

Action: Members to volunteer and nominate individuals for the Task and Finish group to Dr Rob Bracchi

AWPAG Share Care Prescribing and Monitoring Guidance

Kath Haines reported that AW TTC will be liaising with appropriate pharmacists within the health boards for development of shared care protocols for medicines identified to be appropriate for shared care.

9.0 Feedback from the All Wales Chief Pharmacists group

Bethan Tranter informed members that there was an NHS internal review on the way in which medicines are supplied to patients, including inpatients, which was started in July. Bethan Tranter informed members of the areas involved in the review and that recommendations will be formed once the review is completed in March.

10.0 Any other business (Chair to have been informed prior to the meeting)

SHARE platform

Christine Collier updated members on the SHARE platform and reminded members how it can be accessed. Members were informed that the videos of the Best Practice Day presentations were now all uploaded onto SHARE. Christine Collier informed members that there is a section on the platform for discussing the Low Priority for Funding

DRAFT

document; AWPAG members will be invited to access this in order to view the draft document and discuss the development of the resource.

Action: Christine Collier to send out the SHARE link to members

The Chair asked members if anyone else had anything to raise.

Sian Evans suggested inviting someone to talk to AWPAG about the possible results of a Brexit 'deal' or 'no deal'. Bethan Tranter informed members that the December meeting would be too late for Health Boards to implement anything. The group thought this would still be a good idea, even if it was for information purposes only.

Action: Sian Evans to forward Kath Haines the contact details for the presenter.

No other issues were raised.

11.0 Date of next meeting: Wednesday 5 December 2018

The Chair informed members that the next meeting would take place at the Angel Hotel, Cardiff on Wednesday, 5th December 2018.

The Chair closed the meeting.